Born in a Pandemic.
Built for Every Year After It.

In the depths of the COVID-19 pandemic, our founders kept returning to the same conviction: there had to be a better way. The world had built its antiviral playbook one virus at a time, always a step behind the threat in front of it. What if a medicine could be designed ahead of the threat, and address what ails us today, working across many viruses at once instead of starting over with each new one?

That belief is why Decoy exists. We are pioneering a new category of antivirals, Designable Multi-Antivirals, or D-MAVs^TM: single, adaptable medicines engineered to target the mechanisms many viruses share, so one drug can work across many of them. We build them on the IMP³ACT^TM platform, which pairs AI-enabled design with rapid synthesis, so candidates can move toward the clinic faster and the pipeline grows rather than restarts.